May 8, 2026
Clinical Updates
Auvelity® (dextromethorphan/bupropion) – New indication
April 30, 2026 - The FDA announced the approval of Axsome Therapeutics’ Auvelity (dextromethorphan/bupropion), for the treatment of agitation associated with dementia due to Alzheimer’s disease.
Drug Approvals
Edarbi® (azilsartan kamedoxomil) – First-time authorized brand alternative
April 28, 2026 - Wilshire Pharmaceuticals launched an authorized brand alternative of Edarbi (azilsartan kamedoxomil) tablets.
Drug Approvals
Jakafi XR™ (ruxolitinib) – New formulation approval
May 1, 2026 - Incyte announced the FDA approval of Jakafi XR (ruxolitinib), a new extended-release formulation of ruxolitinib.
Drug Approvals
Langlara™ (insulin glargine-aldy) – New biosimilar approval
April 29, 2026 - Lanexa Biologics and Sunshine Lake Pharma announced the FDA approval of Langlara (insulin glargine-aldy), biosimilar and interchangeable to Sanofi Aventis’ Lantus® SoloStar® (insulin glargine).
Drug Approvals
Veppanu (vepdegestrant) – New drug approval
May 1, 2026 - The FDA announced the approval of Arvinas/Pfizer’s Veppanu (vepdegestrant), for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Drug Recalls - Availability
Trividia Health – Recall of True Metrix® Self-Monitoring Blood glucose meters
April 28, 2026 - Trividia Health announced a voluntary, consumer level recall of all True Metrix, True Metrix Air, True Metrix Go self-monitoring blood glucose systems and True Metrix Pro professional monitoring blood glucose system. This recall also includes cobranded products sold under store or distribution partner names. The recall is due to an issue with software design of the E-5 Error Code.